{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T21:32:56Z","timestamp":1764019976446,"version":"3.37.3"},"reference-count":34,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,11,11]],"date-time":"2014-11-11T00:00:00Z","timestamp":1415664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pain Practice"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To determine prior authorization (PA) impact on healthcare utilization, costs, and pharmacologic treatment patterns for painful diabetic peripheral neuropathy (<jats:styled-content style=\"fixed-case\">pDPN<\/jats:styled-content>) and fibromyalgia (FM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective, observational, longitudinal cohort study used medical and pharmacy claims data. Newly diagnosed patients treated for FM or <jats:styled-content style=\"fixed-case\">pDPN<\/jats:styled-content> between 7\/1\/2007 and 12\/31\/2011 were included. PA and no PA groups were matched by propensity score 4:1. Medical resource utilization, direct medical and pharmacy costs, and treatment pattern differences were compared. Pre and postindex differences between PA and no PA cohorts were determined by difference in difference analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Analysis of 2,315 FM patients (1,852 PA; 463 no PA) demonstrated greater increases in postindex all\u2010cause costs ($197; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.6673) and disease\u2010related costs ($72; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.4186) in the PA cohort. Analysis of 1,300 <jats:styled-content style=\"fixed-case\">pDPN<\/jats:styled-content> patients (1,040 PA; 260 no PA) demonstrated postindex all\u2010cause cost increases of $1,155 more in the no PA cohort (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.6248); disease\u2010related costs decreased $2,809 more in the no PA cohort (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.4312). Treatment patterns were similar between cohorts; opioid usage was higher in the FM PA cohort (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.0082).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>There was no evidence of statistically significant differences between PA and no PA cohorts in either FM or <jats:styled-content style=\"fixed-case\">pDPN<\/jats:styled-content> populations for total all\u2010cause or disease\u2010related costs.<\/jats:p><\/jats:sec>","DOI":"10.1111\/papr.12258","type":"journal-article","created":{"date-parts":[[2014,11,11]],"date-time":"2014-11-11T10:56:59Z","timestamp":1415703419000},"source":"Crossref","is-referenced-by-count":4,"title":["Prior Authorization in the Treatment of Patients with <scp>pDPN<\/scp> and FM"],"prefix":"10.1111","volume":"15","author":[{"given":"Hilary E. D.","family":"Placzek","sequence":"first","affiliation":[{"name":"Industry Sponsored Research HealthCore, Inc. Andover Massachusetts U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth T.","family":"Masters","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Pfizer, Inc. New York New York U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Gu","sequence":"additional","affiliation":[{"name":"Industry Sponsored Research HealthCore, Inc. Wilmington Delaware U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph C.","family":"Cappelleri","sequence":"additional","affiliation":[{"name":"Statistics Pfizer, Inc. Groton Connecticut U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Wasser","sequence":"additional","affiliation":[{"name":"Biostatistics HealthCore, Inc. Wilmington Delaware U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew G.","family":"Clair","sequence":"additional","affiliation":[{"name":"Pfizer, Inc. New York New York U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph P.","family":"Cook","sequence":"additional","affiliation":[{"name":"Pfizer, Inc. New York New York U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra F.","family":"Eisenberg","sequence":"additional","affiliation":[{"name":"Industry Sponsored Research HealthCore, Inc. Wilmington Delaware U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,11,11]]},"reference":[{"key":"e_1_2_5_2_1","unstructured":"International Association for the Study of Pain[homepage on the Internet].IASP Taxonomy.Washington:International Association for the Study of Pain;2011[updated 2012 May 22]. Available from:http:\/\/www.iasp-pain.org\/Content\/NavigationMenu\/GeneralResourceLinks\/PainDefinitions\/default.htm."},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc05-2228"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/papr.12054"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330203"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23176"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20140"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-6773.2007.00774.x"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa030954"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-9134.2005.00080.x"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000178216.23514.b7"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E380"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.19.2344"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.23.1.227"},{"key":"e_1_2_5_15_1","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/01.MLR.0000053022.47132.82","article-title":"Effect of tiered prescription copayment on the use of preferred brand medications","volume":"41","author":"Rector TS","year":"2003","journal-title":"Med Care"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.w2.408"},{"key":"e_1_2_5_17_1","first-page":"447","article-title":"Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans","volume":"16","author":"Margolis JM","year":"2010","journal-title":"Am J Manag Care."},{"key":"e_1_2_5_18_1","first-page":"e95","article-title":"Effects of a Medicaid prior authorization policy for pregabalin","volume":"15","author":"Margolis JM","year":"2009","journal-title":"Am J\u00a0Manag Care."},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.11.031"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/70.1.41"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"volume-title":"Fundamentals of Biostatistics","year":"2011","author":"Rosner B","key":"e_1_2_5_23_1"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.793692"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/papr.12073"},{"key":"e_1_2_5_26_1","first-page":"250","article-title":"Pharmacist and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program","volume":"16","author":"Jacobson VJ","year":"2010","journal-title":"J Manage Care Pharm."},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1086\/655890"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-14-109"},{"key":"e_1_2_5_29_1","unstructured":"JohnstonSS UdallM AlvirJ et\u00a0al.Association between Pregabalin Access Restrictions and Pain\u2010Related Healthcare Expenditures in Medicare Supplemental Health Plans. Poster presented at The Academy of Managed Care Pharmacy 2012 Educational Conference October 3\u20105 2012 Cincinnati Ohio."},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2009.03.013"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3182863447"},{"volume-title":"Guideline for the Management of Fibromyalgia Syndrome Pain in Adults and Children","year":"2005","author":"Buckhardt CS","key":"e_1_2_5_32_1"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.071522"},{"key":"e_1_2_5_34_1","unstructured":"JohnstonSS SadoskyA CappelleriJC JohnsonBH ShradyG SilvermanSL.Pregabalin Prior Authorization and Medication Interactions. Poster presented at the American Academy of Pain Management September 26\u201029 2013 Orlando Florida."},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwt010"}],"container-title":["Pain Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpapr.12258","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/papr.12258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T21:36:28Z","timestamp":1696282588000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/papr.12258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,11]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1111\/papr.12258"],"URL":"https:\/\/doi.org\/10.1111\/papr.12258","archive":["Portico"],"relation":{},"ISSN":["1530-7085","1533-2500"],"issn-type":[{"type":"print","value":"1530-7085"},{"type":"electronic","value":"1533-2500"}],"subject":[],"published":{"date-parts":[[2014,11,11]]}}}